Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

Arjun Vasant Balar, Ronald de Wit, Girish S. Kulkarni et al.|The Lancet Oncology|2021

Cited by 532